<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35990">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638038</url>
  </required_header>
  <id_info>
    <org_study_id>INT131-RU01-2</org_study_id>
    <nct_id>NCT02638038</nct_id>
  </id_info>
  <brief_title>This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years</brief_title>
  <official_title>A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InteKrin Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InteKrin Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, parallel group study comparing two doses of INT131( 3 mg
      and 1 mg) administered orally (PO) daily (QD) versus placebo 1 tablet PO QD in subjects with
      treatment-naïve RRMS for ≤ 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, parallel group study comparing two doses of INT131( 3 mg
      and 1 mg) administered orally (PO) daily (QD) versus placebo 1 tablet PO QD in subjects with
      treatment-naïve RRMS for ≤ 3 years..

      Part 2 of the study is open-label, Subjects completing 6 months of evaluations and study
      drug in Part 1 without serious study drug-related treatment emergent adverse events (TEAE)
      will be switched to INT131 1 mg PO QD and followed for an additional 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized double blind parallel group study with 3mg, 1mg or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The number of new gadolinium CE T1 weighted lesions</measure>
    <time_frame>asline to 6 months</time_frame>
    <description>The mean number of new gadolinium CE T1-weighted lesions, on monthly MRI in subjects receiving INT131 compared to Placebo from baseline to 6 months.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Multiple Sclerosis, Relapsing Remitting</condition>
  <arm_group>
    <arm_group_label>Oral INT 131 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral INT-131 Double blind study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral INT-131 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral INT-131 Double blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo Double blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INT131</intervention_name>
    <description>INT- 131</description>
    <arm_group_label>Oral INT 131 3 mg</arm_group_label>
    <arm_group_label>Oral INT-131 1 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent before any study procedures

          2. Male and female subjects aged 18-50

          3. Subjects with a diagnosis of RRMS of three (3) years or less based on date of
             diagnosis

          4. At least one gadolinium-positive lesion within twelve months of enrollment in the
             study documented in subject's clinical chart

        Exclusion Criteria:

          1. Subjects with a history or presence of chronic disease of the immune system other
             than RRMS

          2. Subjects with a diagnosis of primary or secondary progressive multiple sclerosis

          3. Ten (10) or more active gadolinium CE MRI-detected lesions on baseline MRI obtained
             on visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara K. Finck, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Coherus BioSciences (parent company for Zao InteKrin)</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>December 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
